Free  Phasing out patient leaflets in paper form: eco-responsible or irresponsible?

Marketing Authorisations

Selinexor (Nexpovio°) in relapsed or refractory multiple myeloma

Lonafarnib (Zokinvy°) in progeria

Semaglutide injections (Wegovy°) in obesity in adolescents

Avapritinib (Ayvakyt°) in advanced systemic mastocytosis

Bimekizumab (Bimzelx°) in axial spondyloarthritis or psoriatic arthritis

Olipudase alfa (Xenpozyme°) in acid sphingomyelinase deficiency type B or A/B

Topiramate and risks associated with pregnancy: European measures

Omega-3 polyunsaturated fatty acids: dose-dependent risk of atrial fibrillation downplayed in the SmPCs

Bupropion + naltrexone (Mysimba°) for weight loss: set to be withdrawn from the market in the European Union?

Pseudoephedrine-containing medicines in the common cold: the EMA misses an opportunity to protect patients

Setmelanotide (Imcivree°) in Bardet-Biedl syndrome

Adverse Effects

In-utero exposure to corticosteroids: increased risk of serious infections during the first year of life

Opioid replacement therapy during pregnancy: buprenorphine appears less dangerous than methadone for the unborn child

Sertaconazole or econazole during pregnancy: no particular safety signal for the unborn child

CAR T-cell therapies: secondary T-cell lymphomas

Caftors: depression, anxiety, suicide

Common stem: -relin, -relix

Outlook

Prescrire's review of drug packaging in 2023: reconciling ease of use with safety is an ongoing challenge

Prescrire's contribution to the EMA's consultation on the "Concept Paper for the Development of a Guideline on Non-Inferiority and Equivalence Comparisons in Clinical Trials"

Masthead

Free  Masthead